Page last updated: 2024-10-24
celecoxib and Respiratory Tract Neoplasms
celecoxib has been researched along with Respiratory Tract Neoplasms in 1 studies
Respiratory Tract Neoplasms: New abnormal growth of tissue in the RESPIRATORY SYSTEM.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 7.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
| "Recurrent respiratory papillomas, caused by human papillomaviruses, are premalignant tumors that overexpress the epidermal growth factor receptor (EGFR)." | 3.73 | Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. ( Abramson, AL; Dannenberg, AJ; Shikowitz, MJ; Steinberg, BM; Wu, R, 2005) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Wu, R | 1 |
| Abramson, AL | 1 |
| Shikowitz, MJ | 1 |
| Dannenberg, AJ | 1 |
| Steinberg, BM | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis[NCT00571701] | Phase 2 | 50 participants (Actual) | Interventional | 2008-02-29 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Correlation Between Mean Plasma Level of Celecoxib and Response.
Mean plasma levels of celecoxib over months 3-12 in first treatment period correlated with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | pg. celecoxib/ml. plasma (Mean) |
|---|
| Responders | 151.3 |
| Non-responders | 543.41 |
Effect of Gender on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.
Percent of patients of each gender with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to12 months
| Intervention | percent responders (Number) |
|---|
| Celecoxib First - Males | 12.50 |
| Placebo First- Males | 40.00 |
| Celecoxib First- Females | 12.50 |
| Placebo First- Females | 0.00 |
Effect of HPV 6 Versus HPV 11 on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%
Percent of patients with HPV 6 versus patients with HPV 11 with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent of responders (Number) |
|---|
| Celecoxib First - HPV 6 | 9.09 |
| Placebo First- HPV 6 | 42.86 |
| Celecoxib First- HPV 11 | 25.00 |
| Placebo First- HPV 11 | 0.00 |
Effect of Juvenile Versus Adult Disease Onset on Percent of Patients With Reduction in Papilloma Growth Rate Greater Than 50%.
Percent of juvenile versus adult onset patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percentage of responders (Number) |
|---|
| Celecoxib First- Juvenile Onset | 12.50 |
| Placebo First- Juvenile-onsent | 7.69 |
| Celecoxib First - Adult Onset | 12.50 |
| Placebo First- Adult-onset | 33.33 |
Maintenance of Response Following Discontinuation of Celecoxib
Percent of patients who responded to celecoxib with increase in papilloma growth rate of no greater than 0.01 at end of second treatment period compared to growth rate at end of first treatment period. (NCT00571701)
Timeframe: End of first treatment period (month 12) to end of second treatment period (month 24)
| Intervention | percent of patients (Number) |
|---|
| Celecoxib Responders-maintained | 100 |
Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline
Change in mean growth rates during the last 3 months of the first treatment period compared to the mean values at baseline. Endoscopy and removal of all tumor was done every 3 months. Growth rate is calculated as the scored amount of papilloma recurrence in a 3 month period divided by the exact number of days since last endoscopy and removal of all tumor. (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent change in mean growth rate (Mean) |
|---|
| Celecoxib First, Then Placebo | -5.4 |
| Placebo First, Then Celecoxib | -15.2 |
Percent of Patients With Positive Response to Treatment
Percent of patients with reduction in papilloma growth rate greater than 50% during the last 3 months of first treatment period compared to baseline (NCT00571701)
Timeframe: Baseline to 12 months
| Intervention | percent responders (Number) |
|---|
| Celecoxib First (12 Months), Then Placebo (12 Months) | 12.5 |
| Placebo First (12 Months), Then Celecoxib (12 Months) | 28.6 |
Other Studies
1 other study available for celecoxib and Respiratory Tract Neoplasms